Literature DB >> 12242536

Prognosis of patients after hemicraniectomy in malignant middle cerebral artery infarction.

Birgit Walz1, Carolin Zimmermann, Stefanie Böttger, Roman L Haberl.   

Abstract

BACKGROUND AND
PURPOSE: There are unsatisfactory therapeutic options for treatment of large infarctions of the middle cerebral artery with secondary development of life threatening brain edema. In most cases, post-ischemic brain edema can not be adequately treated by conservative means. However, several studies have shown that operative procedures such as decompressive hemicraniectomy can decrease mortality. Apart from mortality, the morbidity and quality of life are major features with which to estimate therapeutic benefit. The aim of this study was to acquire follow-up data on quality of life and outcome in patients treated with hemicraniectomy after stroke.
METHODS: Eighteen patients were treated with decompressive hemicraniectomy after life threatening middle cerebral artery infarction between July 1997 and April 2000 in our clinic. Six patients (33 %) died within the first six months after the procedure. All twelve surviving patients were seen in a follow-up examination 7 to 26 months after the stroke and tested using the Rankin-Scale, Barthel Index (BI), Aachener Life Quality Inventory (ALQI) and Zung Self-Rating Depression Scale.
RESULTS: Survivors with a mean age of 40.7 +/- 16.5 years were significantly younger than non-survivors with a mean age of 64.5 +/- 9.2 years (p = 0.006). Mean Barthel-Index of surviving patients was 61.1 +/- 26.1 points, mean Rankin-Scale 3.3 +/- 1.2 points. Two patients were able to return to work. Patients younger than 45 years (n = 7) had a significantly better outcome (BI 75.7 +/- 20.7) than patients over 45 years (n = 5) (BI 42.0 +/- 22.7 points, p = 0.026). Among five patients with an infarction of the left hemisphere, four had a slight to moderate Broca aphasia and one patient a global aphasia. Quality of life assessment by ALQI showed moderate disability (58.0 +/- 22.7 of 107 points) with no significant difference between left- and right-hemispheric infarctions. Using the Zung Self-Rating Depression Scale six patients were ranked as slightly depressive, one patient as moderately depressive and five patients as not depressive. Eleven out of twelve survivors, as well as their relatives, approved of the decision to have the operation.
CONCLUSIONS: The study provides evidence that hemicraniectomy as treatment of severe space occupying ischemic brain edema saves lives and results in good quality of life in a high proportion of patients, especially in the young. This conclusion is restricted by the lack of a control group, which was deemed unethical in studying a potentially life saving therapy.

Entities:  

Mesh:

Year:  2002        PMID: 12242536     DOI: 10.1007/s00415-002-0798-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

Review 1.  Hemicraniectomy for middle cerebral artery infarction.

Authors:  Hagen B Huttner; Eric Jüttler; Stefan Schwab
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

2.  Early computed tomography features in extensive middle cerebral artery territory infarct: prediction of survival.

Authors:  W W M Lam; T W H Leung; W C W Chu; D T K Yeung; L K S Wong; W S Poon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

3.  Evidence-based guidelines for the management of large hemispheric infarction : a statement for health care professionals from the Neurocritical Care Society and the German Society for Neuro-intensive Care and Emergency Medicine.

Authors:  Michel T Torbey; Julian Bösel; Denise H Rhoney; Fred Rincon; Dimitre Staykov; Arun P Amar; Panayiotis N Varelas; Eric Jüttler; DaiWai Olson; Hagen B Huttner; Klaus Zweckberger; Kevin N Sheth; Christian Dohmen; Ansgar M Brambrink; Stephan A Mayer; Osama O Zaidat; Werner Hacke; Stefan Schwab
Journal:  Neurocrit Care       Date:  2015-02       Impact factor: 3.210

4.  Patient Age and the Outcomes after Decompressive Hemicraniectomy for Stroke: A Nationwide Inpatient Sample Analysis.

Authors:  Hormuzdiyar H Dasenbrock; Faith C Robertson; M Ali Aziz-Sultan; Donovan Guittieres; Rose Du; Ian F Dunn; William B Gormley
Journal:  Neurocrit Care       Date:  2016-12       Impact factor: 3.210

5.  Functional, cognitive and emotional long-term outcome of patients with ischemic stroke requiring mechanical ventilation.

Authors:  Eva Schielke; Markus A Busch; Thomas Hildenhagen; Martin Holtkamp; Ingeborg Küchler; Lutz Harms; Florian Masuhr
Journal:  J Neurol       Date:  2005-03-07       Impact factor: 4.849

6.  Retrospective agreement and consent to neurocritical care is influenced by functional outcome.

Authors:  Ines C Kiphuth; Martin Köhrmann; Joji B Kuramatsu; Christoph Mauer; Lorenz Breuer; Peter D Schellinger; Stefan Schwab; Hagen B Huttner
Journal:  Crit Care       Date:  2010-07-30       Impact factor: 9.097

7.  Quality of life and neurobehavioral changes in survivors of malignant middle cerebral artery infarction.

Authors:  Bessy Benejam; Juan Sahuquillo; Maria Antonia Poca; Laura Frascheri; Elisabeth Solana; Pilar Delgado; Carme Junqué
Journal:  J Neurol       Date:  2009-03-14       Impact factor: 4.849

8.  DESTINY-S: attitudes of physicians toward disability and treatment in malignant MCA infarction.

Authors:  Hermann Neugebauer; Claire J Creutzfeldt; J Claude Hemphill; Peter U Heuschmann; Eric Jüttler
Journal:  Neurocrit Care       Date:  2014-08       Impact factor: 3.210

9.  Emergent Clipping without Prophylactic Decompressive Craniectomy in Patients with a Large Aneurysmal Intracerebral Hematoma.

Authors:  Sung Don Kang
Journal:  J Korean Neurosurg Soc       Date:  2008-12-31

10.  Outcome and prognostic factors of hemicraniectomy for space occupying cerebral infarction.

Authors:  E Uhl; F W Kreth; B Elias; A Goldammer; R G Hempelmann; M Liefner; G Nowak; M Oertel; K Schmieder; G-H Schneider
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.